Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > Strategic transactions
View:
Post by Georgealphabeta on Jan 14, 2012 2:34am

Strategic transactions

ISA  in AUG/13 had debenture issued at 7%  payable to 3SBio ( that might be converted to ISA shares at any point of of time at C
.155 by 3SBio). In 2009 ISA entered in to agreement with Palladin where Palladin acquired position  bought at $.015 later sold to ILJIN @
.26. Recently ISA entered into agreement with VIFOR (the details of the agreement are being kept confidential), what is interesting that Peter Wijngaard of Vifor, is former director of Roche Pharma ( Roche cancelled agreement wit ISA in 2008) in charge of "global alliances) whatever that supposed to mean.LOL. And Vifor is an arm of Galenica, another powerhose pharma business based in Swiss just like Roche  (by the way Novartis of Swiss owns 30% of Roche). So it seems that we have some interest in tiny ISA from people associated with pharma powerhouses that make ILJIN look like a dwarf. Now here it starts to be interesting, I understand that by Jan/28 ILJIN contractually should increase they positon in ISA, however the latest agreement beetwen VIFOR and ISA seems to muscled out ILJIN out of the picture, funny thing is that in the past ILJIN muscled Palladin out of the picture pretty much the same way. And the same way Palladin muscled itself in helpless ISA after Roche stopped financing ISA back in 2008. Here we come in to some stock technical analyses, basically trading patterns from past two weeks that seem to be identical or similiar to previous trading patterns from 2009- 2012 taken  from periods preceding ISA alliances with Palladin and ILJIN. The thing is that latest release suggest that ILJIN considers fighting back. Since some magic financial forces put a cup on stock prices at
.15 or so and revelant informations are "confidential" I guess we will have to wait for few more weeks to see what will come out as a result of this brew, but it seems like big boys are here :-). Anyway this is all speculations and nothing might come out as a result:-).Cheers
Comment by narcissist on Jan 17, 2012 5:35pm
You are right - it is all speculation. But it's indeed true that tiny ISA is in a real sense a minor player now. The future of this stock is in the hands of Swiss, Korean, Chinese, and US players. These 'big boys' as you refer to them are definitely in the play. This is a far different scene than in the past. It is certainly non-productive to muse over the future based on decisions ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities